Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683423 · ClinicalTrials.gov registry record · Phase 2
BMS-741672 for Diabetic Neuropathic Pain
A Phase 2 study of Neuropathic Pain, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 8
- Study locations
NCT00683423: Completed Phase 2 study of Neuropathic Pain, sponsored by Bristol-Myers Squibb.
NCT00683423 is a Phase 2 study of Neuropathic Pain that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 50 participants, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (50% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683423, a Phase 2 study of Neuropathic Pain, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the study is to determine whether BMS-741672 improves neuropathic pain in diabetic patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-741672
Study Locations (8)
Florida
- Palm Beach Neurological Center - Palm Beach Gardens
- Comprehensive Neurosciences, Inc. - St. Petersburg
California
- University Clinical Investigators, Inc. - Tustin
Illinois
- The Pain & Rehabilitation Clinic Of Chicago - Chicago
Nevada
- Advanced Biomedical Research Of America - Las Vegas
North Carolina
- Physicians East P.A. - Greenville
Ohio
- Neurology Center Of Ohio - Toledo
Texas
- Research Institute Of Dallas, P.A. - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00683423 record still lists
NCT00683423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00683423 lists 8 locations in 7 states (Florida, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT00683423 about?
NCT00683423 is a clinical study titled "BMS-741672 for Diabetic Neuropathic Pain". The purpose of the study is to determine whether BMS-741672 improves neuropathic pain in diabetic patients.
What is the current status of trial NCT00683423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-07. Estimated completion is 2009-02.
What conditions does trial NCT00683423 study?
This clinical trial studies the following conditions: Neuropathic Pain.
What interventions are being tested in trial NCT00683423?
The interventions under investigation include: Placebo (DRUG), BMS-741672 (DRUG).
Who is sponsoring clinical trial NCT00683423?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00683423 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Nevada, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00683423's enrollment target sits among peer trials
50 14th of 35 higher than 22 of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
RECRUITING · Phase 2
-
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
RECRUITING · Phase 2
-
Ginger Root Extract for Sciatic Pain Individuals
RECRUITING · Phase 2
-
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 2
-
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia